HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 may improve the production of CAR-T cell therapies. The study was carried out ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

AI automation, and more skilled staff are needed to ensure cancer patients can access potentially life-saving CAR T therapies.

RADNOR, Pa. and PHILADELPHIA, Oct. 15, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and ...

Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Fresenius and Charles River Laboratories are among 18 academic, research, industry and clinical partners that have formed a new European Union-supported consortium to develop an automated, ...

As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

For decades, advanced medical breakthroughs have followed a familiar pattern: scientific discovery, clinical promise, followed at length by broad patient access–if it comes at all. Cancer treatments ...